PPARG and neoplasm: 15(S)-HETE drives peritoneal macrophages toward an anti-tumor phenotype via the PPARγ/C/EBPβ axis (268), while genipin inhibits CCR2 signaling through PPARγ-mediated p65 degradation, reducing macrophage infiltration and preventing hepatocellular carcinoma recurrence (269).